Cetuximab and biomarkers in non-small-cell lung carcinoma
- PMID: 22904614
- PMCID: PMC3421478
- DOI: 10.2147/BTT.S24217
Cetuximab and biomarkers in non-small-cell lung carcinoma
Abstract
Cancer progression is a highly complex process that is driven by a constellation of deregulated signaling pathways and key molecular events. In non-small-cell lung cancer (NSCLC), as in several other cancer types, the epidermal growth factor receptor (EGFR) and its downstream signaling components represent a key axis that has been found not only to trigger cancer progression but also to support advanced disease leading to metastasis. Two major therapeutic approaches comprising monoclonal antibodies and small molecule tyrosine kinase inhibitors have so far been used to target this pathway, with a combination of positive, negative, and inconsequential results, as judged by patient survival indices. Since these drugs are expensive and not all patients derive benefits from taking them, it has become both pertinent and paramount to identify biomarkers that can predict not only beneficial response but also resistance. This review focuses on the chimeric monoclonal antibody, cetuximab, its application in the treatment of NSCLC, and the biomarkers that may guide its use in the clinical setting. A special emphasis is placed on the EGFR, including its structural and mechanistic attributes.
Keywords: NSCLC; biomarker; cancer progression; cetuximab.
Figures
Similar articles
-
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.BMC Med. 2012 Mar 21;10:28. doi: 10.1186/1741-7015-10-28. BMC Med. 2012. PMID: 22436374 Free PMC article.
-
The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805. Clin Cancer Res. 2005. PMID: 15701870
-
Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.Drugs Today (Barc). 2005 Feb;41(2):107-27. doi: 10.1358/dot.2005.41.2.882662. Drugs Today (Barc). 2005. PMID: 15821783 Review.
-
Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).Rev Recent Clin Trials. 2006 Jan;1(1):1-13. doi: 10.2174/157488706775246157. Rev Recent Clin Trials. 2006. PMID: 18393776 Review.
-
Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.J Thorac Oncol. 2010 Nov;5(11):1855-8. doi: 10.1097/JTO.0b013e3181f0bee0. J Thorac Oncol. 2010. PMID: 20975380 Clinical Trial.
Cited by
-
Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy.J Cancer. 2013 Nov 23;4(9):736-54. doi: 10.7150/jca.7734. J Cancer. 2013. PMID: 24312144 Free PMC article. Review.
-
Biodistribution, pharmacokinetics and radioimmunotherapy of 188Re-cetuximab in NCI-H292 human lung tumor-bearing nude mice.Invest New Drugs. 2019 Oct;37(5):961-972. doi: 10.1007/s10637-018-00718-8. Epub 2019 Jan 5. Invest New Drugs. 2019. PMID: 30612308
-
Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles.Oncotarget. 2015 Apr 20;6(11):8788-806. doi: 10.18632/oncotarget.3554. Oncotarget. 2015. PMID: 25871395 Free PMC article.
-
Anti-EGFR monoclonal antibody Cetuximab displays potential anti-cancer activities in feline oral squamous cell carcinoma cell lines.Front Vet Sci. 2022 Nov 17;9:1040552. doi: 10.3389/fvets.2022.1040552. eCollection 2022. Front Vet Sci. 2022. PMID: 36467642 Free PMC article.
-
Synthesis and evaluation of 64Cu-radiolabeled NOTA-cetuximab (64Cu-NOTA-C225) for immuno-PET imaging of EGFR expression.Chin J Cancer Res. 2019 Apr;31(2):400-409. doi: 10.21147/j.issn.1000-9604.2019.02.14. Chin J Cancer Res. 2019. PMID: 31156310 Free PMC article.
References
-
- Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr. Accessed May 24, 2011.
-
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917. - PubMed
-
- Laskin JJ, Sandler AB, Johnson DH. Non-Small Cell Lung Cancer. Philadelphia, PA: Saunders; 2005.
-
- Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol. 2005;23(14):3175–3185. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous